Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3742
Name bladder squamous cell carcinoma
Definition A carcinoma of bladder that is manifested in squamous cells of the bladder.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma bladder squamous cell carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03430895 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Completed USA 0
NCT03697850 Phase II Atezolizumab Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (BladderSpar) Active, not recruiting FRA 0
NCT03866382 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting USA 1
NCT03912818 Phase II Cisplatin + Durvalumab + Gemcitabine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine Carboplatin + Durvalumab + Gemcitabine Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Terminated USA 0
NCT05038657 Phase II Atezolizumab Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). (AURORA) Recruiting GBR 0
NCT05756569 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Recruiting USA 0
NCT06041503 Phase II Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors Not yet recruiting USA 0
NCT06161532 Phase II Atezolizumab + Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer Recruiting USA 0
NCT06528483 Phase II Sacituzumab govitecan-hziy + Zimberelimab Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer (preSAVE) Not yet recruiting ITA 0